Literature DB >> 15078862

Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination?

Minghao Ye1, Jan Wysocki, Parveen Naaz, Mohammad Reza Salabat, Michael S LaPointe, Daniel Batlle.   

Abstract

Unlike the ubiquitous angiotensin-converting enzyme (ACE), the ACE-related carboxypeptidase 2 (ACE 2) is predominantly expressed in the heart, kidney, and testis. ACE 2 degrades angiotensin (Ang) II to Ang (1-7) and Ang I to Ang (1-9). We investigated the expression of ACE and ACE 2 in a rodent model of type 2 diabetes. ACE and ACE 2 were measured in kidney and heart from 8-week-old no diabetic control (db/m) mice and diabetic (db/db) mice, which at this young age have obesity and hyperglycemia without nephropathy. In renal cortical tissue, ACE mRNA was reduced (db/db 0.31+/-0.06 versus db/m 0.99+/-0.05; P<0.005), whereas ACE 2 mRNA was not (db/db 0.94+/-0.05 versus db/m 1.03+/-0.11, NS). ACE protein was markedly reduced in kidney cortex of db/db mice (db/db 0.24+/-0.13 versus db/m 1.02+/-0.12; P<0.005), and this was associated with a corresponding decrease in renal ACE activity (db/db 12.7+/-3.7 versus db/m 61.6+/-4.4 mIU/mg protein; P<0.001). ACE 2 protein, by contrast, was increased in kidneys from diabetic mice (db/db 1.39+/-0.14 versus db/m 0.53+/-0.04; P<0.005). An increase in ACE 2 protein and a decrease in ACE protein, respectively, were also seen by immunostaining of renal cortical tubules from the db/db mice. In heart tissue, there were no significant differences between db/db and db/m mice in either ACE mRNA and protein or ACE 2 mRNA and protein. We conclude that in young db/db mice, ACE 2 protein in renal cortical tubules is increased, whereas ACE protein is decreased. We propose that the pattern of low ACE protein coupled with increased ACE 2 protein expression may be renoprotective in early stages of diabetes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15078862     DOI: 10.1161/01.HYP.0000126192.27644.76

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  85 in total

1.  Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2.

Authors:  Minghao Ye; Jan Wysocki; Francisco R Gonzalez-Pacheco; Mahmoud Salem; Karla Evora; Laura Garcia-Halpin; Marko Poglitsch; Manfred Schuster; Daniel Batlle
Journal:  Hypertension       Date:  2012-07-09       Impact factor: 10.190

Review 2.  ACE and ACE2 in kidney disease.

Authors:  Sonoo Mizuiri; Yasushi Ohashi
Journal:  World J Nephrol       Date:  2015-02-06

3.  Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney.

Authors:  Nadja Grobe; Khalid M Elased; David R Cool; Mariana Morris
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-07       Impact factor: 4.310

4.  Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice.

Authors:  Susan B Gurley; Alicia Allred; Thu H Le; Robert Griffiths; Lan Mao; Nisha Philip; Timothy A Haystead; Mary Donoghue; Roger E Breitbart; Susan L Acton; Howard A Rockman; Thomas M Coffman
Journal:  J Clin Invest       Date:  2006-07-27       Impact factor: 14.808

5.  Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice.

Authors:  Esam S B Salem; Nadja Grobe; Khalid M Elased
Journal:  Am J Physiol Renal Physiol       Date:  2014-01-22

6.  Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy.

Authors:  G Wang; F M-M Lai; K-B Lai; K-M Chow; C-H B Kwan; K-T P Li; C-C Szeto
Journal:  Diabetologia       Date:  2008-04-04       Impact factor: 10.122

7.  Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension.

Authors:  Jan Wysocki; Minghao Ye; Eva Rodriguez; Francisco R González-Pacheco; Clara Barrios; Karla Evora; Manfred Schuster; Hans Loibner; K Bridget Brosnihan; Carlos M Ferrario; Josef M Penninger; Daniel Batlle
Journal:  Hypertension       Date:  2009-11-30       Impact factor: 10.190

Review 8.  The sweeter side of ACE2: physiological evidence for a role in diabetes.

Authors:  Sharell M Bindom; Eric Lazartigues
Journal:  Mol Cell Endocrinol       Date:  2008-10-01       Impact factor: 4.102

9.  Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition.

Authors:  Elena Velkoska; Rachael G Dean; Luke Burchill; Vicki Levidiotis; Louise M Burrell
Journal:  Clin Sci (Lond)       Date:  2010-02       Impact factor: 6.124

10.  Human recombinant ACE2 reduces the progression of diabetic nephropathy.

Authors:  Gavin Y Oudit; George C Liu; Jiuchang Zhong; Ratnadeep Basu; Fung L Chow; Joyce Zhou; Hans Loibner; Evelyne Janzek; Manfred Schuster; Josef M Penninger; Andrew M Herzenberg; Zamaneh Kassiri; James W Scholey
Journal:  Diabetes       Date:  2009-11-23       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.